ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Announces Second Quarter 2017 Financial Results

August 9, 2017

ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies

August 3, 2017

ContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants

July 20, 2017

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

July 19, 2017

ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017

June 1, 2017

ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave

May 30, 2017

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

May 25, 2017

ContraFect Announces First Quarter 2017 Financial Results

May 8, 2017

ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

April 19, 2017

ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program

March 30, 2017

RSS
  • « Previous
  • 1...
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • ...23
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter